RNC Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,873 shares of the company’s stock after buying an additional 184 shares during the period. RNC Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,247,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in MRK. JJJ Advisors Inc. acquired a new stake in Merck & Co., Inc. in the second quarter valued at about $27,000. PRW Wealth Management LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $41,000. Aspire Private Capital LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $55,000. Thor Advisors LLC acquired a new stake in Merck & Co., Inc. in the first quarter valued at about $69,000. Finally, Contravisory Investment Management Inc. lifted its position in Merck & Co., Inc. by 19.7% in the second quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock valued at $72,000 after purchasing an additional 141 shares during the period. Institutional investors and hedge funds own 75.16% of the company’s stock.
In related news, CFO Robert M. Davis sold 216,718 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the sale, the chief financial officer now owns 354,378 shares in the company, valued at $30,274,512.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by company insiders.
Shares of MRK traded down $0.32 during mid-day trading on Wednesday, reaching $84.03. 351,130 shares of the company’s stock were exchanged, compared to its average volume of 10,401,444. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.06 and a current ratio of 1.37. The stock’s 50-day simple moving average is $83.30. Merck & Co., Inc. has a 52-week low of $65.68 and a 52-week high of $87.07. The company has a market cap of $217.48 billion, a P/E ratio of 19.35, a price-to-earnings-growth ratio of 1.72 and a beta of 0.56.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 42.84%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. During the same period last year, the company posted $1.06 EPS. The company’s revenue was up 12.4% on a year-over-year basis. On average, equities research analysts predict that Merck & Co., Inc. will post 4.91 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.62%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 50.69%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Read More: Golden Cross
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.